Login / Signup

Efficacy and safety of selpercatinib in Chinese patients with advanced RET fusion-positive non-small-cell lung cancer: a phase II clinical trial (LIBRETTO-321).

Shun LuYing ChengDingzhi HuangYuping SunLin WuChengzhi ZhouYe GuoJingxin ShaoWanli ZhangJianying Zhou
Published in: Therapeutic advances in medical oncology (2022)
fusion-positive NSCLC, consistent with LIBRETTO-001 (ClinicalTrials.gov: NCT04280081).
Keyphrases
  • phase ii
  • clinical trial
  • open label
  • small cell lung cancer
  • double blind
  • phase iii
  • placebo controlled
  • study protocol
  • advanced non small cell lung cancer
  • tyrosine kinase